IP Library Granted Patent US 12,343,501
Granted Patent B2
US 12,343,501 · App. 18/316,703 · Granted Jul 1, 2025

Techniques to reduce risk of occlusions in drug delivery systems

Inventors: Yibin Zheng (Hartland, WI); Joon Bok Lee (Acton, MA); Jason O'Connor (Acton, MA)
Assignee: INSULET CORPORATION
A61M5/172A61K38/28A61M5/14248G05B15/02G05D7/0623G05D7/0676G16H20/17G16H40/67A61M2205/18A61M2205/3331A61M2205/3584A61M2205/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,501
App. No.
18/316,703
Granted
Jul 1, 2025
Kind
B2
Abstract

Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.

Claims (51)

1. A non-transitory computer readable medium embodied with programming code executable by a processor, and the processor when executing the programming code is operable to:

receive a first control instruction from a controller to deliver a first dosage of a liquid drug by a pump mechanism of a delivery device;

determine a first number of pump mechanism pulses needed to deliver the first dosage of the liquid drug;

determine a remainder of the first dosage of the liquid drug unable to be delivered based upon the first number of pump mechanism pulses;

output a first actuation command to actuate the pump mechanism to deliver the first dosage of the liquid drug minus the remainder of the first dosage of the liquid drug;

receive a second control instruction to deliver a second dosage of the liquid drug from the pump mechanism;

determine a second number of pump mechanism pulses needed to deliver the remainder of the first dosage of the liquid drug plus at least a portion of the second dosage; and

output a second actuation command to actuate the pump mechanism to deliver the remainder of the first dosage of the liquid drug plus the at least a portion of the second dosage.

2. The non-transitory computer readable medium of claim 1 , wherein the processor, when executing the programming code is further operable to:

determine a second number of pump mechanism pulses needed to deliver the second dosage of the liquid drug;

determine a remainder of the second dosage of the liquid drug unable to be delivered based upon the second number of pump mechanism pulses; and

add the remainder of the second dosage of the liquid drug to a future dosage to be delivered by the pump mechanism.

3. The non-transitory computer readable medium of claim 1 , wherein the processor, when executing the programming code is further operable to:

determine an undelivered remainder of one or more dosages of the liquid drug during a past time period; and

cause the determined underdelivered remainder to be delivered in a future time period.

4. The non-transitory computer readable medium of claim 1 , wherein the first number of pump mechanism pulses needed to deliver the first dosage of the liquid drug is based upon a resolution of the pump mechanism, and the resolution comprises a fixed amount of liquid drug caused to be output by one pump mechanism pulse.

5. The non-transitory computer readable medium of claim 4 , wherein the resolution further comprises a predetermined period of time to deliver the fixed amount of liquid drug.

6. The non-transitory computer readable medium of claim 1 , wherein the delivery device comprises a housing and the controller is contained within the housing.

7. The non-transitory computer readable medium of claim 1 , wherein the controller is a personal diabetes manager, a smartphone, or a smartwatch remote from the delivery device.

8. The non-transitory computer readable medium of claim 1 , wherein the first control instruction is received during a first time period representing a first control cycle.

9. The non-transitory computer readable medium of claim 8 , wherein the second control instruction is received during a second time period representing a second control cycle.

10. The non-transitory computer readable medium of claim 9 , wherein the first control cycle and the second control cycle are of equal duration.

11. A drug delivery device, comprising:

a reservoir operable to hold a liquid drug;

a cannula coupled to the reservoir via a fluid delivery path and operable to deliver the liquid drug to a user;

a pump mechanism coupled to the reservoir and operable to deliver the liquid drug from the reservoir via the fluid delivery path and through the cannula;

a memory operable to store programming code, a delivery control application, and data;

a controller communicatively coupled to the pump mechanism and the memory, and operable to execute the programming code and the delivery control application; and

a communication device operable to wirelessly communicate with an external device and communicatively coupled to the controller, wherein:

the controller, when executing the delivery control application, is operable to:

receive a first control instruction from a controller to deliver a first dosage of a liquid drug by a pump mechanism of a delivery device;

determine a first number of pump mechanism pulses needed to deliver the first dosage of the liquid drug;

determine a remainder of the first dosage of the liquid drug unable to be delivered based upon the first number of pump mechanism pulses;

output a first actuation command to actuate the pump mechanism to deliver the first dosage of the liquid drug minus the remainder of the first dosage of the liquid drug;

receive a second control instruction to deliver a second dosage of the liquid drug from the pump mechanism;

determine a second number of pump mechanism pulses needed to deliver the remainder of the first dosage of the liquid drug plus at least a portion of the second dosage; and

output a second actuation command to actuate the pump mechanism to deliver the remainder of the first dosage of the liquid drug plus the at least a portion of the second dosage.

12. The drug delivery device of claim 11 , wherein the processor, when executing the programming code is further operable to:

determine a second number of pump mechanism pulses needed to deliver the second dosage of the liquid drug;

determine a remainder of the second dosage of the liquid drug unable to be delivered based upon the second number of pump mechanism pulses; and

add the remainder of the second dosage of the liquid drug to a future dosage to be delivered by the pump mechanism.

13. The drug delivery device of claim 11 , wherein the processor, when executing the programming code is further operable to:

determine an undelivered remainder of one or more dosages of the liquid drug during a past time period; and

cause the determined underdelivered remainder to be delivered in a future time period.

14. The drug delivery device of claim 11 , wherein the first number of pump mechanism pulses needed to deliver the first dosage of the liquid drug is based upon a resolution of the pump mechanism, and the resolution comprises a fixed amount of liquid drug caused to be output by one pump mechanism pulse.

15. The drug delivery device of claim 14 , wherein the resolution further comprises a predetermined period of time to deliver the fixed amount of liquid drug.

16. The drug delivery device of claim 11 , wherein the delivery device comprises a housing and the controller is contained within the housing.

17. The drug delivery device of claim 11 , wherein the controller is a personal diabetes manager, a smartphone, or a smartwatch remote from the delivery device.

18. The drug delivery device of claim 11 , wherein the first control instruction is received during a first time period representing a first control cycle.

19. The drug delivery device of claim 18 , wherein the second control instruction is received during a second time period representing a second control cycle.

20. The drug delivery device of claim 19 , wherein the first control cycle and the second control cycle are of equal duration.

Assignments (2)
SECURITY AGREEMENT SUPPLEMENT Recorded Sep 7, 2023
From: INSULET CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 064840/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2023
From: ZHENG, YIBIN; O'CONNOR, JASON; LEE, JOON BOK
To: INSULET CORPORATION
Reel/Frame 063630/0268 →
Continuity (2)
Continuation 16945246 · Jul 31, 2020
Related Publication 20230277766A1 · Sep 7, 2023
References Cited (2)
US 10610643B2 · Mazlish · 2020 [cited by examiner]
US 11707567B2 · Kamen · 2023 [cited by examiner]
Cited By (1)
US 12,661,488